NP delivers again !!!. So now we are basket Trial, the flood gates start to open … How long can everybody out there ignore CYDY ??

Quote:

---

Bruce Patterson, M.D., Chief Executive Officer of IncellDX and science advisor to CytoDyn stated: “CytoDyn will file for expanded access IND for patients with pancreatic, prostate, lung, breast, liver or melanoma cancers because we have been able to detect immune cell infiltrates expressing CCR5 that could impair the immune response against the tumor if CCR5 is not blocked. Having the ability to detect and quantify these target cell infiltrates puts leronlimab squarely in the personalized immune-oncology arena with a mechanism of action common to many tumors.”

---

Quote:

---

A Basket Trial involves a single investigational drug or drug combination that is studied across multiple cancer populations defined by disease stage, histology, number of prior therapies, genetic or other biomarkers, or demographic characteristics. It is usually designed as a single-arm, activity-estimating trial with overall response rate as the primary endpoint. A strong response signal seen in a sub-study may allow for expansion to generate data that could potentially support a marketing approval.

---